The aim of this study was to evaluate the safety and clinical outcomes associated with stereotactic surgical implantation of modified bone marrow–derived mesenchymal stem cells (SB623) in patients with stable chronic ischemic stroke.
This was a 2-year, open-label, single-arm, phase 1/2a study; the selected patients had chronic motor deficits between 6 and 60 months after nonhemorrhagic stroke. SB623 cells were administered to the target sites surrounding the subcortical stroke region using MRI stereotactic image guidance.
A total of 18 patients were treated with SB623 cells. All experienced at least 1 treatment-emergent adverse event (TEAE). No patients withdrew due to adverse events, and there were no dose-limiting toxicities or deaths. The most frequent TEAE was headache related to the surgical procedure (88.9%). Seven patients experienced 9 serious adverse events, which resolved without sequelae. In 16 patients who completed 24 months of treatment, statistically significant improvements from baseline (mean) at 24 months were reported for the European Stroke Scale (ESS) score, 5.7 (95% CI 1.4–10.1, p < 0.05); National Institutes of Health Stroke Scale (NIHSS) score, −2.1 (95% CI −3.3 to −1.0, p < 0.01), Fugl-Meyer (F-M) total score, 19.4 (95% CI 9.9–29.0, p < 0.01); and F-M motor scale score, 10.4 (95% CI 4.0–16.7, p < 0.01). Measures of efficacy reached plateau by 12 months with no decline thereafter. There were no statistically significant changes in the modified Rankin Scale score. The size of transient lesions detected by T2-weighted FLAIR imaging in the ipsilateral cortex at weeks 1–2 postimplantation significantly correlated with improvement in ESS (0.619, p < 0.05) and NIHSS (−0.735, p < 0.01) scores at 24 months.
In this completed 2-year phase 1/2a study, implantation of SB623 cells in patients with stable chronic stroke was safe and was accompanied by improvements in clinical outcomes.
Correspondence Gary Steinberg: Stanford University School of Medicine and Stanford Healthcare, Stanford, CA. firstname.lastname@example.org.
INCLUDE WHEN CITING Published online November 23, 2018; DOI: 10.3171/2018.5.JNS173147.
Disclosures This study was partly conducted at Stanford University School of Medicine and Stanford Health Care (SHC) and was funded by a contract with SanBio, Inc., which provided principal investigator, co-investigator, and coordinator fees. Dr. Steinberg and Dr. Schwartz are Stanford University School of Medicine employees. Dr. Steinberg is a consultant for Qool Therapeutics, Peter Lazic US, Inc., and NeuroSave.
This study was partly conducted at the University of Pittsburgh Medical School and University of Pittsburgh Medical Center (UPMC), and was funded by a contract with SanBio, Inc., which provided principal investigator and coordinator fees. Dr. Wechsler and Dr. Lunsford are employees of the University of Pittsburgh Medical School and UPMC. Dr. Kondziolka is a former employee of UPMC, and was a consultant for Elekta AB. Dr. Wechsler is a stockholder in Silk Road Medical and Remedy Pharm, is a consultant for Athersys and SanBio, Inc., and receives unrelated grant funding from Athersys, Inc. Dr. Lunsford is a consultant for and stockholder of Elekta AB and serves on the DSMB for Insightec. Personnel support for a principal investigator in this study was provided by the University of California, San Francisco, and was funded by a contract with SanBio, Inc. Dr. Kim is an employee of the University of California, San Francisco, and receives unrelated grant funding from BioGen Idec. Dr. Bates and Dr. McGrogan are full-time employees of SanBio, Inc. Dr. Poggio received consultancy fees from SanBio, Inc. and owns Biostatistical Consulting Inc., which provides statistical services to SanBio Inc. Dr. Case and Dr. Yankee are former employees and current stockholders of SanBio, Inc. Dr. Yankee is a consultant for SanBio, Inc. Dr. McGrogan is a stockholder of SanBio, Inc.
BaluS: Differences in psychometric properties, cut-off scores, and outcomes between the Barthel Index and Modified Rankin Scale in pharmacotherapy-based stroke trials: systematic literature review. Curr Med Res Opin25:1329–13412009
BenjaminEJBlahaMJChiuveSECushmanMDasSRDeoR: Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation135:e146–e6032017(Errata in Circulation 135:e646 2017; Circulation 136:e196 2017)
DouketisJDSpyropoulosACSpencerFAMayrMJafferAKEckmanMH: Perioperative management of antithrombotic therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest141 (2 Suppl):e326S–e350S2012
FeysHMDe WeerdtWJSelzBECox SteckGASpichigerRVereeckLE: Effect of a therapeutic intervention for the hemiplegic upper limb in the acute phase after stroke: a single-blind, randomized, controlled multicenter trial. Stroke29:785–7921998
LoACGuarinoPKrebsHIVolpeBTBeverCTDuncanPW: Multicenter randomized trial of robot-assisted rehabilitation for chronic stroke: methods and entry characteristics for VA ROBOTICS. Neurorehabil Neural Repair23:775–7832009
PowersWJDerdeynCPBillerJCoffeyCSHohBLJauchEC: American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association Focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke46:3020–30352015
RaiATSeldonAEBooSLinkPSDomicoJRTarabishyAR: A population-based incidence of acute large vessel occlusions and thrombectomy eligible patients indicates significant potential for growth of endovascular stroke therapy in the USA. J Neurointerv Surg9:722–7262017
SteinbergGKKondziolkaDWechslerLRLunsfordLDCoburnMLBilligenJB: Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. Stroke47:1817–18242016
SullivanKJTilsonJKCenSYRoseDKHershbergJCorreaA: Fugl-Meyer assessment of sensorimotor function after stroke: standardized training procedure for clinical practice and clinical trials. Stroke42:427–4322011
TajiriNKanekoYShinozukaKIshikawaHYankeeEMcGroganM: Stem cell recruitment of newly formed host cells via a successful seduction? Filling the gap between neurogenic niche and injured brain site. PLoS One8:e748572013
van der LeeJHWagenaarRCLankhorstGJVogelaarTWDevilléWLBouterLM: Forced use of the upper extremity in chronic stroke patients: results from a single-blind randomized clinical trial. Stroke30:2369–23751999
YasuharaTMatsukawaNHaraKMakiMAliMMYuSJ: Notch-induced rat and human bone marrow stromal cell grafts reduce ischemic cell loss and ameliorate behavioral deficits in chronic stroke animals. Stem Cells Dev18:1501–15142009